{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T15:59:59Z","timestamp":1786982399515,"version":"build-2736575974"},"reference-count":25,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2025,4,11]],"date-time":"2025-04-11T00:00:00Z","timestamp":1744329600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,4,11]],"date-time":"2025-04-11T00:00:00Z","timestamp":1744329600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Neth Heart J"],"published-print":{"date-parts":[[2025,5]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>While randomised trials have shown that surgical and transcutaneous aortic valve replacement\/implantation (SAVR\/TAVI) have similar short- to mid-term outcomes, long-term outcome data are scarce. Additionally, no large-scale long-term follow-up data from Dutch databases and TAVI centres have been reported to inform national guidelines.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We retrospectively analysed baseline characteristics, 5\u2011year mortality and re-intervention rates of patients undergoing isolated SAVR or TAVI, stratified by age (65\u201375, 75\u201380 and &gt;\u202f80\u00a0years old) in the Netherlands Heart Registry.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      From 2013 through 2021, 7879 SAVR patients (median age: 73.0 years; interquartile range (IQR): 69.0\u201377.0; 43.7% female) and 14,461 TAVI patients (median age: 81.0 years; IQR: 77.0\u201384.0; 49.9% female) were treated in the Netherlands. Patients undergoing TAVI more frequently had chronic obstructive pulmonary disease, diabetes, atrial fibrillation, dialysis, poor mobility, previous stroke, unstable angina and recent myocardial infarction compared with SAVR patients. This higher comorbidity rate in TAVI was observed across all age groups. After 5\u2011year follow-up, mortality rates were higher after TAVI compared with SAVR (35.5% vs 13.0%;\n                      <jats:italic>p<\/jats:italic>\n                      \u202f&lt;\u20090.001). This difference decreased with increasing age (\n                      <jats:italic>p<\/jats:italic>\n                      \u00a0for interaction &lt;\u202f0.001). While the aortic re-intervention rate was low in both cohorts, it was higher after SAVR than TAVI (1.9% vs 0.9%;\n                      <jats:italic>p<\/jats:italic>\n                      \u202f&lt;\u20090.001).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Demographics of patients undergoing SAVR versus TAVI in the Netherlands differed substantially. TAVI patients were older and had more comorbidities than SAVR patients, across all age groups. Mortality rates were highest after TAVI, while aortic re-intervention was more common after SAVR. These findings reflect differences in baseline patient characteristics and current daily practice in decision-making by the Heart Teams.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1007\/s12471-025-01944-5","type":"journal-article","created":{"date-parts":[[2025,4,11]],"date-time":"2025-04-11T04:25:56Z","timestamp":1744345556000},"page":"172-179","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Long-term age-stratified outcomes after surgical and transcatheter aortic valve replacement: a\u00a0Dutch cohort study"],"prefix":"10.1007","volume":"33","author":[{"given":"Kees","family":"van Bergeijk","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stijn","family":"Venema","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ad","family":"van den Heuvel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rik","family":"van der Werf","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wobbe","family":"Bouma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yvonne","family":"Douglas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Niki","family":"Medendorp","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marijke","family":"Timmermans","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adriaan","family":"Voors","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joanna J.","family":"Wykrzykowska","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"Transcatheter Heart valve Interventions and Cardiothoracic Surgery Registration Committee of the Netherlands Heart Registry","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,4,11]]},"reference":[{"key":"1944_CR1","doi-asserted-by":"publisher","first-page":"2912","DOI":"10.1093\/eurheartj\/ehab375","volume":"42","author":"TH J\u00f8rgensen","year":"2021","unstructured":"J\u00f8rgensen\u00a0TH, Thyregod\u00a0HGH, Ihlemann\u00a0N, et\u00a0al. Eight-year outcomes for patients with aortic valve stenosis at low surgical risk randomized to transcatheter vs. surgical aortic valve replacement. Eur Heart\u00a0J. 2021;42:2912\u20139.","journal-title":"Eur Heart J"},{"key":"1944_CR2","first-page":"1","volume":"00","author":"Y Ahmad","year":"2023","unstructured":"Ahmad\u00a0Y, Howard\u00a0JP, Arnold\u00a0AD, et\u00a0al. Transcatheter versus surgical aortic valve replacement in lower-risk and higher-risk patients: a\u00a0meta-analysis of randomized trials. Eur Heart\u00a0J. 2023;00:1\u201317.","journal-title":"Eur Heart J"},{"key":"1944_CR3","doi-asserted-by":"publisher","first-page":"2163","DOI":"10.1016\/j.jacc.2023.09.813","volume":"82","author":"JK Forrest","year":"2023","unstructured":"Forrest\u00a0JK, Deeb\u00a0GM, Yakubov\u00a0SJ, et\u00a0al. 4\u2011Year Outcomes of Patients With Aortic Stenosis in the Evolut Low Risk Trial. J\u00a0Am Coll Cardiol. 2023;82:2163\u20135.","journal-title":"J Am Coll Cardiol"},{"key":"1944_CR4","doi-asserted-by":"publisher","first-page":"1949","DOI":"10.1056\/NEJMoa2307447","volume":"389","author":"MJ Mack","year":"2023","unstructured":"Mack MJ, Leon MB, Thourani VH, et al. Transcatheter Aortic-Valve Replacement in Low-Risk Patients at Five Years. N\u00a0Engl J Med. 2023;389:1949\u201360.","journal-title":"N Engl J Med"},{"key":"1944_CR5","first-page":"1","volume":"2021","author":"A Vahanian","year":"2021","unstructured":"Vahanian\u00a0A, Beyersdorf\u00a0F, Praz\u00a0F, et\u00a0al. ESC\/EACTS Guidelines for the management of valvular heart disease. Eur Heart\u00a0J. 2021;2021:1\u201372.","journal-title":"Eur Heart J"},{"key":"1944_CR6","unstructured":"ZIN-Criteria https:\/\/www.zorginstituutnederland.nl\/publicaties\/publicatie\/2020\/11\/18\/indicatie-richtlijn-tavi-2020."},{"key":"1944_CR7","doi-asserted-by":"publisher","first-page":"2054","DOI":"10.1016\/j.jacc.2022.08.787","volume":"80","author":"T Sharma","year":"2022","unstructured":"Sharma\u00a0T, Krishnan\u00a0AM, Lahoud\u00a0R, Polomsky\u00a0M, Dauerman\u00a0HL. National Trends in TAVR and SAVR for Patients With Severe Isolated Aortic Stenosis. J\u00a0Am Coll Cardiol. 2022;80:2054\u20136.","journal-title":"J Am Coll Cardiol"},{"key":"1944_CR8","doi-asserted-by":"publisher","first-page":"1139","DOI":"10.1093\/ejcts\/ezab216","volume":"60","author":"F Beyersdorf","year":"2021","unstructured":"Beyersdorf\u00a0F, Bauer\u00a0T, Freemantle\u00a0N, et\u00a0al. Five-year outcome in 18 010 patients from the German Aortic Valve Registry. Eur J Cardiothorac Surg. 2021;60:1139\u201346.","journal-title":"Eur J Cardiothorac Surg"},{"key":"1944_CR9","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1161\/CIRCINTERVENTIONS.119.007825","volume":"12","author":"M Barbanti","year":"2019","unstructured":"Barbanti\u00a0M, Tamburino\u00a0C, D\u2019Errigo\u00a0P, et\u00a0al. Five-Year Outcomes of Transfemoral Transcatheter Aortic Valve Replacement or Surgical Aortic Valve Replacement in a\u00a0Real World Population. Circ Cardiovasc Interv. 2019;12:12\u2013e7825.","journal-title":"Circ Cardiovasc Interv"},{"key":"1944_CR10","doi-asserted-by":"publisher","first-page":"546","DOI":"10.1007\/s12471-022-01672-0","volume":"30","author":"MJC Timmermans","year":"2022","unstructured":"Timmermans\u00a0MJC, Houterman\u00a0S, Daeter\u00a0ED, et\u00a0al. Using real-world data to monitor and improve quality of care in coronary artery disease: results from the Netherlands heart registration. Neth Heart\u00a0J. 2022;30:546\u201356.","journal-title":"Neth Heart J"},{"key":"1944_CR11","doi-asserted-by":"publisher","first-page":"996","DOI":"10.4244\/EIJ-D-22-00493","volume":"18","author":"M Vanhaverbeke","year":"2022","unstructured":"Vanhaverbeke\u00a0M, S\u00f8ndergaard\u00a0L, De Backer\u00a0O. Life expectancy of patients with a\u00a0transcatheter aortic valve and the implications for long-term valve durability data collection. EuroIntervention. 2022;18:996\u20138.","journal-title":"EuroIntervention"},{"key":"1944_CR12","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1007\/s12471-023-01811-1","volume":"31","author":"R Eerdekens","year":"2023","unstructured":"Eerdekens\u00a0R, van Steenbergen\u00a0G, El Farissi\u00a0M, et\u00a0al. National indication document and aortic valve replacement landscape in the Netherlands. Neth Heart\u00a0J. 2023;31:473\u20138.","journal-title":"Neth Heart J"},{"key":"1944_CR13","doi-asserted-by":"publisher","first-page":"1889","DOI":"10.1016\/j.jacc.2023.08.044","volume":"82","author":"G Prosperi-Porta","year":"2023","unstructured":"Prosperi-Porta\u00a0G, Nguyen\u00a0V, Willner\u00a0N, et\u00a0al. Association of Age and Sex With Use of Transcatheter Aortic Valve Replacement in France. J\u00a0Am Coll Cardiol. 2023;82:1889\u2013902.","journal-title":"J Am Coll Cardiol"},{"key":"1944_CR14","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/j.ahj.2020.06.016","volume":"228","author":"H Eltchaninoff","year":"2020","unstructured":"Eltchaninoff\u00a0H, Bonaros\u00a0N, Prendergast\u00a0B, et\u00a0al. Rationale and design of a\u00a0prospective, randomized, controlled, multicenter study to evaluate the safety and efficacy of transcatheter heart valve replacement in female patients with severe symptomatic aortic stenosis requiring aortic valve intervention (Randomized researcH in womEn all comers wIth Aortic stenosis (RHEIA) trial). Am Heart\u00a0J. 2020;228:27\u201335.","journal-title":"Am Heart J"},{"key":"1944_CR15","doi-asserted-by":"publisher","first-page":"1572","DOI":"10.1056\/NEJMoa2400685","volume":"2;390","author":"S Blankenberg","year":"2024","unstructured":"Blankenberg\u00a0S, Seiffert\u00a0M, Vonthein\u00a0R, et\u00a0al. Transcatheter or Surgical Treatment of Aortic-Valve Stenosis. N\u00a0Engl J Med. 2024;2;390:1572\u201383.","journal-title":"N Engl J Med"},{"key":"1944_CR16","doi-asserted-by":"publisher","first-page":"1116","DOI":"10.1093\/eurheartj\/ehae043","volume":"45","author":"HG H\u00f8rsted Thyregod","year":"2024","unstructured":"H\u00f8rsted Thyregod\u00a0HG, J\u00f8rgensen\u00a0TH, Ihlemann\u00a0N, et\u00a0al. Transcatheter or surgical aortic valve implantation: 10-year outcomes of the NOTION trial. Eur Heart\u00a0J. 2024;45:1116\u201324.","journal-title":"Eur Heart J"},{"key":"1944_CR17","doi-asserted-by":"publisher","first-page":"778","DOI":"10.1080\/00015385.2023.2218025","volume":"78","author":"DY Park","year":"2023","unstructured":"Park\u00a0DY, An\u00a0S, Kassab\u00a0K, et\u00a0al. Chronological comparison of TAVI and SAVR stratified to surgical risk: a\u00a0systematic review, meta-analysis, and meta-regression. Acta Cardiol. 2023;78:778\u201389.","journal-title":"Acta Cardiol"},{"key":"1944_CR18","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1016\/j.amjcard.2021.07.046","volume":"158","author":"H Ueyama","year":"2021","unstructured":"Ueyama\u00a0H, Kuno\u00a0T, Takagi\u00a0H, et\u00a0al. Meta-Analysis Comparing Valve Durability Among Different Transcatheter and Surgical Aortic Valve Bioprosthesis. Am J Cardiology. 2021;158:104\u201311.","journal-title":"Am J Cardiology"},{"key":"1944_CR19","doi-asserted-by":"crossref","first-page":"E277","DOI":"10.1002\/ccd.24597","volume":"83","author":"NM Van Mieghem","year":"2014","unstructured":"Van Mieghem\u00a0NM, Van Der Boon\u00a0RM, Nuis\u00a0RJ, et\u00a0al. Cause of death after transcatheter aortic valve implantation. Catheter Cardiovasc Interv. 2014;83:E277\u201382.","journal-title":"Catheter Cardiovasc Interv"},{"key":"1944_CR20","first-page":"157","volume":"10","author":"TT Lerman","year":"2023","unstructured":"Lerman\u00a0TT, Levi\u00a0A, Talmor-Barkan\u00a0Y, Kornowski\u00a0R. Early and Mid-Term Outcomes of Transcatheter Aortic Valve Implantation versus Surgical Aortic Valve Replacement: Updated Systematic Review and Meta-Analysis. J\u00a0Cardiovasc Dev Dis. 2023;10:157.","journal-title":"J Cardiovasc Dev Dis"},{"key":"1944_CR21","doi-asserted-by":"publisher","first-page":"1000","DOI":"10.1001\/jamacardio.2022.2695","volume":"7","author":"NM Van Mieghem","year":"2022","unstructured":"Van Mieghem\u00a0NM, Deeb\u00a0GM, Sondergaard\u00a0L, et\u00a0al. Self-expanding Transcatheter vs Surgical Aortic Valve Replacement in Intermediate-Risk Patients: 5\u2011Year Outcomes of the SURTAVI Randomized Clinical Trial. JAMA Cardiol. 2022;7:1000\u20138.","journal-title":"JAMA Cardiol"},{"key":"1944_CR22","doi-asserted-by":"publisher","first-page":"103624","DOI":"10.1016\/j.amsu.2022.103624","volume":"77","author":"S Corona","year":"2022","unstructured":"Corona\u00a0S, Manganiello\u00a0S, Pepi\u00a0M, et\u00a0al. Bioprosthetic aortic valve replacement in patients aged 50\u00a0years old and younger: Structural valve deterioration at long-term follow-up. Retrospective study. Ann Med Surg. 2022;77:103624.","journal-title":"Ann Med Surg"},{"issue":"9","key":"1944_CR23","doi-asserted-by":"publisher","first-page":"e018506","DOI":"10.1161\/JAHA.120.018506","volume":"2020","author":"AE Kostyunin","year":"2020","unstructured":"Kostyunin\u00a0AE, Yuzhalin\u00a0AE, Rezvova\u00a0MA, et\u00a0al. Degeneration of Bioprosthetic Heart Valves: Update. J\u00a0Am Heart Assoc. 2020;2020(9):e18506.","journal-title":"J Am Heart Assoc"},{"key":"1944_CR24","doi-asserted-by":"publisher","first-page":"1017","DOI":"10.1016\/j.jtcvs.2018.02.092","volume":"156","author":"X Armoiry","year":"2018","unstructured":"Armoiry\u00a0X, Obadia\u00a0JF, Pascal\u00a0L, Polazzi\u00a0S, Duclos\u00a0A. Comparison of transcatheter versus surgical aortic valve implantation in high-risk patients: A\u00a0nationwide study in France. J\u00a0Thorac Cardiovasc Surg. 2018;156:1017\u20131025.e4.","journal-title":"J Thorac Cardiovasc Surg"},{"key":"1944_CR25","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1016\/j.amjcard.2021.02.031","volume":"148","author":"T Ando","year":"2021","unstructured":"Ando\u00a0T, Onishi\u00a0T, Kuno\u00a0T, et\u00a0al. Transcatheter Versus Surgical Aortic Valve Replacement in the United States (From the Nationwide Readmission Database). Am J Cardiol. 2021;148:110\u20135.","journal-title":"Am J Cardiol"}],"container-title":["Netherlands Heart Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12471-025-01944-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12471-025-01944-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12471-025-01944-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,22]],"date-time":"2025-04-22T09:43:52Z","timestamp":1745315032000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12471-025-01944-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,11]]},"references-count":25,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2025,5]]}},"alternative-id":["1944"],"URL":"https:\/\/doi.org\/10.1007\/s12471-025-01944-5","relation":{},"ISSN":["1568-5888","1876-6250"],"issn-type":[{"value":"1568-5888","type":"print"},{"value":"1876-6250","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,4,11]]},"assertion":[{"value":"18 February 2025","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 April 2025","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"W.\u00a0Bouma has received support for attending meetings and\/or travel from Edwards Lifesciences and Atricure. A.\u00a0Voors has received research grants from AnaCardio, Bayer, BMS, Boehringer Ingelheim, Corteria, Cytokinetics, Eli Lilly, Merck, Novartis, Novo Nordisk, Roche Diagnostics, Pfizer and Moderna and consulting fees from AnaCardio, Bayer, BMS, Boehringer Ingelheim, Corteria, Cytokinetics, Eli Lilly, Merck, Novartis, Novo Nordisk and Roche Diagnostics. J.J.\u00a0Wykrzykowska has received research grants paid to the University Medical Centre Groningen from Medtronic and US2.ai and consulting fees paid to the University Medical Centre Groningen from BSC, Abbot, Meril, Medtronic, Novo Nordisk, SMT, Sinomed and Medis. K.\u00a0van Bergeijk, S.\u00a0Venema, A.\u00a0van den Heuvel, R.\u00a0van der Werf, Y.\u00a0Douglas, N.\u00a0Medendorp and M.\u00a0Timmermans, declare that they have no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}